Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:AMRN NASDAQ:CADL NASDAQ:DSGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.45+4.7%$1.37$0.86▼$3.36$87.53M0.14322,664 shs98,882 shsAMRNAmarin$15.39+2.4%$15.63$7.08▼$17.49$318.16M0.7791,802 shs34,606 shsCADLCandel Therapeutics$5.01+2.1%$5.99$3.79▼$14.60$275.38M-0.91.02 million shs745,384 shsDSGNDesign Therapeutics$6.53+6.8%$4.48$2.60▼$7.77$371.59M1.61136,070 shs143,595 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-0.72%+5.34%+1.47%+15.00%-42.50%AMRNAmarin-0.07%-2.40%-0.66%+18.16%+23.00%CADLCandel Therapeutics-4.31%-15.98%-20.75%-19.04%-19.57%DSGNDesign Therapeutics+2.52%+8.33%+50.49%+52.37%+27.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.45+4.7%$1.37$0.86▼$3.36$87.53M0.14322,664 shs98,882 shsAMRNAmarin$15.39+2.4%$15.63$7.08▼$17.49$318.16M0.7791,802 shs34,606 shsCADLCandel Therapeutics$5.01+2.1%$5.99$3.79▼$14.60$275.38M-0.91.02 million shs745,384 shsDSGNDesign Therapeutics$6.53+6.8%$4.48$2.60▼$7.77$371.59M1.61136,070 shs143,595 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-0.72%+5.34%+1.47%+15.00%-42.50%AMRNAmarin-0.07%-2.40%-0.66%+18.16%+23.00%CADLCandel Therapeutics-4.31%-15.98%-20.75%-19.04%-19.57%DSGNDesign Therapeutics+2.52%+8.33%+50.49%+52.37%+27.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$7.00384.43% UpsideAMRNAmarin 1.50Reduce$12.00-22.00% DownsideCADLCandel Therapeutics 3.00Buy$20.00299.60% UpsideDSGNDesign Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ABOS, CADL, DSGN, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.008/25/2025ABOSAcumen PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$23.006/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$7.00 ➝ $12.006/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/AAMRNAmarin$228.61M1.39N/AN/A$23.62 per share0.65CADLCandel Therapeutics$120K2,289.79N/AN/A$1.41 per share3.55DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)AMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)Latest ABOS, CADL, DSGN, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54-$0.68-$0.14-$0.68N/AN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.265.975.97AMRNAmarinN/A3.262.34CADLCandel Therapeutics0.017.047.04DSGNDesign TherapeuticsN/A25.1325.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%AMRNAmarin22.25%CADLCandel Therapeutics13.93%DSGNDesign Therapeutics56.64%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%AMRNAmarin3.30%CADLCandel Therapeutics16.60%DSGNDesign Therapeutics23.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million54.94 millionOptionableAMRNAmarin36020.68 million20.00 millionOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableABOS, CADL, DSGN, and AMRN HeadlinesRecent News About These CompaniesAlmitas Capital LLC Acquires 129,229 Shares of Design Therapeutics, Inc. $DSGNSeptember 5 at 6:46 AM | marketbeat.comDesign Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5 at 4:01 AM | seekingalpha.comWellington Management Group LLP Purchases Shares of 141,519 Design Therapeutics, Inc. $DSGNSeptember 3 at 3:56 AM | marketbeat.comDriehaus Capital Management LLC Increases Stock Position in Design Therapeutics, Inc. $DSGNSeptember 2 at 5:57 AM | marketbeat.comDesign Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 27, 2025 | globenewswire.comDesign Therapeutics (NASDAQ:DSGN) Trading Up 1.3% - Time to Buy?August 20, 2025 | marketbeat.comLeerink Partnrs Has Negative Forecast for DSGN Q3 EarningsAugust 17, 2025 | marketbeat.comDesign Therapeutics (NASDAQ:DSGN) Announces Earnings Results, Misses Estimates By $0.02 EPSAugust 11, 2025 | marketbeat.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comDesign Therapeutics Inc (DSGN) - Investing.comJuly 10, 2025 | investing.comDesign Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND ApplicationJune 4, 2025 | quiverquant.comQDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2June 4, 2025 | globenewswire.comDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceMay 13, 2025 | globenewswire.comDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3, 2025 | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1, 2025 | globenewswire.comWhy Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%April 25, 2025 | aaii.comADesign Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABOS, CADL, DSGN, and AMRN Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.44 +0.07 (+4.71%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Amarin NASDAQ:AMRN$15.38 +0.36 (+2.36%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Candel Therapeutics NASDAQ:CADL$5.00 +0.11 (+2.14%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Design Therapeutics NASDAQ:DSGN$6.52 +0.42 (+6.79%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
